Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Amarin Corporation

Related AMRN
Stocks To Watch For June 26, 2014
Top Performing Industries For June 12, 2014

In a report published Friday, Canaccord Genuity reiterated its Buy rating on Amarin Corporation (NASDAQ: AMRN), but lowered its price target from $26.00 to $19.00.

Canaccord Genuity noted, “Reiterate BUY, lowering target to $19; maintain positive view on Vascepa commercial, partnering potential while acknowledging increased commercial risk. We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $19 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”

Amarin Corporation closed on Thursday at $11.95.

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters